Pfizer India Reports 6.3% Revenue Growth in Q4; Board Declares ₹75 Dividend

Synopsis: Pfizer Limited reported steady Q4FY26 revenue growth driven by stable pharmaceutical demand and improved product mix. Although reported profit declined due to absence of last year’s exceptional gain, the company maintained healthy operational performance and announced a final dividend of Rs. 75 per share.

Pfizer has a total market capitalization of Rs.21,272.70 crore, according to data on the NSE. Pfizer shares were trading at Rs. 4,650 apiece on the National Stock Exchange, down by 1.61percent; the stock has declined around 2.98 percent over the last five sessions, while it has gone down about 4.16 percent in the 30 days. Over a six-month period, the stock has given a negative return of 7.80 percent, whereas on a year-on-year basis it has increased nearly 7.54 percent, reflecting poor overall performance. The stock’s 52-week high was Rs. 5993 and 52-week low was Rs. 4269.1.

Pfizer Limited reported financial results for the quarter and financial year ended March 31, 2026. The company posted revenue from operations of Rs. 629.23 crore in Q4FY26 compared to Rs. 591.91 crore in Q4FY25, reflecting growth of around 6.3 percent year-on-year. However, Quarter over quarter, revenue declined slightly from Rs. 645.03 crore reported in Q3FY26.

Total income for the quarter stood at Rs. 669.95 crore in Q4FY26 compared to Rs. 636.49 crore in the corresponding quarter last year, registering growth of around 5.3 percent year-on-year. The increase was supported by stable pharmaceutical demand and higher contribution from key products.

On the profitability front, the company reported net profit of Rs. 199.82 crore in Q4FY26 compared to Rs. 330.94 crore in Q4FY25. However, the previous year quarter included a large exceptional gain of Rs. 172.81 crore, which significantly boosted profitability during Q4FY25. Excluding exceptional items, operational profitability improved during Q4FY26. Quarter over quarter, profit increased from Rs. 141.84 crore reported in Q3FY26.

Profit before tax stood at Rs. 268.82 crore in Q4FY26 compared to Rs. 425.80 crore in Q4FY25. The decline was mainly due to absence of the exceptional gain recorded in the previous year quarter. On a normalized basis, the company maintained healthy operational performance supported by controlled expenses and improved product mix.

A key factor supporting margins during the quarter was lower overall operating expenses. Total expenses stood at Rs. 410.17 crore in Q4FY26 compared to Rs. 383.50 crore in Q4FY25. While expenses increased year-on-year due to higher raw material and operational costs, revenue growth and operational efficiency supported profitability.

The company also reported positive inventory adjustments during the quarter. Changes in inventories stood at Rs. 19.63 crore compared to negative Rs. 7.68 crore in Q4FY25, indicating better inventory management and improved product movement.

For the full financial year FY26, Pfizer reported revenue from operations of Rs. 2,519.65 crore compared to Rs. 2,281.35 crore in FY25, reflecting growth of around 10.4 percent year-on-year. Net profit for FY26 stood at Rs. 722.43 crore compared to Rs. 767.60 crore in FY25. The decline was mainly due to exceptional items recorded in the previous financial year.

Profit before tax for FY26 stood at Rs. 975.67 crore compared to Rs. 1,016.09 crore in FY25. Earnings per share (EPS) for FY26 stood at Rs. 157.92 compared to Rs. 167.79 in FY25. The Board of Directors recommended a final dividend of Rs. 75 per equity share having a face value of Rs. 10 each for FY26, representing a payout of 750 percent.

Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The company manufactures products through its own facilities and third-party manufacturers across India and distributes products through independent distributors. Pfizer India is among the largest multinational pharmaceutical companies operating in the Indian market.

India’s pharmaceutical sector continues benefiting from rising healthcare awareness, chronic disease treatment demand, healthcare infrastructure growth and increasing penetration of branded medicines. Multinational pharmaceutical companies with strong product portfolios, brand strength and distribution networks may benefit from long-term structural healthcare growth in India.

However, the pharmaceutical industry remains sensitive to regulatory changes, pricing controls, competition from generics, raw material costs and currency fluctuations. Margin performance also depends on product mix and operational efficiency.

Overall, Pfizer reported stable operational growth during Q4FY26 supported by higher revenue and improved cost management. Going forward, product demand, new launches, pricing environment and operational efficiency will remain key factors influencing the company’s future performance.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pfizer India Reports 6.3% Revenue Growth in Q4; Board Declares ₹75 Dividend appeared first on Trade Brains.